You just read:

CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics

News provided by

CASI Pharmaceuticals, Inc.

Apr 17, 2019, 07:00 ET